Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10

EA. Bates, JA. Davies, J. Váňová, D. Nestić, VS. Meniel, S. Koushyar, TG. Cunliffe, RM. Mundy, E. Moses, HK. Uusi-Kerttula, AT. Baker, DK. Cole, D. Majhen, PJ. Rizkallah, T. Phesse, JD. Chester, AL. Parker

. 2022 ; 25 (-) : 43-56. [pub] 20220316

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22017556

Oncolytic virotherapies (OV) hold immense clinical potential. OV based on human adenoviruses (HAdV) derived from HAdV with naturally low rates of pre-existing immunity will be beneficial for future clinical translation. We generated a low-seroprevalence HAdV-D10 serotype vector incorporating an αvβ6 integrin-selective peptide, A20, to target αvβ6-positive tumor cell types. HAdV-D10 has limited natural tropism. Structural and biological studies of HAdV-D10 knob protein highlighted low-affinity engagement with native adenoviral receptors CAR and sialic acid. HAdV-D10 fails to engage blood coagulation factor X, potentially eliminating "off-target" hepatic sequestration in vivo. We engineered an A20 peptide that selectively binds αvβ6 integrin into the DG loop of HAdV-D10 fiber knob. Assays in αvβ6+ cancer cell lines demonstrated significantly increased transduction mediated by αvβ6-targeted variants compared with controls, confirmed microscopically. HAdV-D10.A20 resisted neutralization by neutralizing HAdV-C5 sera. Systemic delivery of HAdV-D10.A20 resulted in significantly increased GFP expression in BT20 tumors. Replication-competent HAdV-D10.A20 demonstrated αvβ6 integrin-selective cell killing in vitro and in vivo. HAdV-D10 possesses characteristics of a promising virotherapy, combining low seroprevalence, weak receptor interactions, and reduced off-target uptake. Incorporation of an αvβ6 integrin-selective peptide resulted in HAdV-D10.A20, with significant potential for clinical translation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017556
003      
CZ-PrNML
005      
20220720100258.0
007      
ta
008      
220718s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.omto.2022.03.007 $2 doi
035    __
$a (PubMed)35399606
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bates, Emily A $u Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
245    10
$a Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10 / $c EA. Bates, JA. Davies, J. Váňová, D. Nestić, VS. Meniel, S. Koushyar, TG. Cunliffe, RM. Mundy, E. Moses, HK. Uusi-Kerttula, AT. Baker, DK. Cole, D. Majhen, PJ. Rizkallah, T. Phesse, JD. Chester, AL. Parker
520    9_
$a Oncolytic virotherapies (OV) hold immense clinical potential. OV based on human adenoviruses (HAdV) derived from HAdV with naturally low rates of pre-existing immunity will be beneficial for future clinical translation. We generated a low-seroprevalence HAdV-D10 serotype vector incorporating an αvβ6 integrin-selective peptide, A20, to target αvβ6-positive tumor cell types. HAdV-D10 has limited natural tropism. Structural and biological studies of HAdV-D10 knob protein highlighted low-affinity engagement with native adenoviral receptors CAR and sialic acid. HAdV-D10 fails to engage blood coagulation factor X, potentially eliminating "off-target" hepatic sequestration in vivo. We engineered an A20 peptide that selectively binds αvβ6 integrin into the DG loop of HAdV-D10 fiber knob. Assays in αvβ6+ cancer cell lines demonstrated significantly increased transduction mediated by αvβ6-targeted variants compared with controls, confirmed microscopically. HAdV-D10.A20 resisted neutralization by neutralizing HAdV-C5 sera. Systemic delivery of HAdV-D10.A20 resulted in significantly increased GFP expression in BT20 tumors. Replication-competent HAdV-D10.A20 demonstrated αvβ6 integrin-selective cell killing in vitro and in vivo. HAdV-D10 possesses characteristics of a promising virotherapy, combining low seroprevalence, weak receptor interactions, and reduced off-target uptake. Incorporation of an αvβ6 integrin-selective peptide resulted in HAdV-D10.A20, with significant potential for clinical translation.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Davies, James A $u Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
700    1_
$a Váňová, Jana $u Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK $u Department of Genetics and Microbiology, Faculty of Science, Charles University, Viničná 5, 128 44 Prague 2, Czech Republic
700    1_
$a Nestić, Davor $u Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, 10000 Zagreb, Croatia
700    1_
$a Meniel, Valerie S $u European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK
700    1_
$a Koushyar, Sarah $u European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK
700    1_
$a Cunliffe, Tabitha G $u Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
700    1_
$a Mundy, Rosie M $u Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
700    1_
$a Moses, Elise $u Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
700    1_
$a Uusi-Kerttula, Hanni K $u Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
700    1_
$a Baker, Alexander T $u Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
700    1_
$a Cole, David K $u Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
700    1_
$a Majhen, Dragomira $u Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, 10000 Zagreb, Croatia
700    1_
$a Rizkallah, Pierre J $u Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
700    1_
$a Phesse, Toby $u European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK
700    1_
$a Chester, John D $u Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK $u Velindre Cancer Centre, Whitchurch, Cardiff CF14 2TL, UK
700    1_
$a Parker, Alan L $u Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
773    0_
$w MED00209366 $t Molecular therapy oncolytics $x 2372-7705 $g Roč. 25, č. - (2022), s. 43-56
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35399606 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100253 $b ABA008
999    __
$a ind $b bmc $g 1816648 $s 1168798
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 25 $c - $d 43-56 $e 20220316 $i 2372-7705 $m Molecular therapy oncolytics $n Mol Ther Oncolytics $x MED00209366
LZP    __
$a Pubmed-20220718

Find record

Citation metrics

Archiving options